-
2690MO Extended efficacy and safety from the phase III MANEUVER trial of pimicotinib in patients with tenosynovial giant cell tumour (TGCT)2025 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access
Hans A. J. Gelderblom, Javier Martín‐Broto, Zhou Yz, Albiruni Ryan Abdul Razak, R. Saleh, Jie Shen, +10 more
2citations -
594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients2020 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics Open access
Louisa Rose Hoes, Hanneke van der Wijngaart, Jade M. van Berge Henegouwen, Laurien Joanna Zeverijn, Daphne L. van der Velden, Paul Roepman, +14 more
2citations -
1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Irene L. M. Reijers, Petros Dimitriadis, Alexander Maxwell Menzies, Ellen Kapiteijn, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk, +13 more
2citations -
P-384 Quality of life and the systemic pharmacokinetics of oxaliplatin in patients with unresectable peritoneal metastases from colorectal cancer treated with repetitive electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC): The CRC-PIPAC trial2020 Annals of Oncology conference-abstract Medicine Intraperitoneal and Appendiceal Malignancies Open access
Robin J. Lurvink, Koen P. B. Rovers, Rudaba Tajzai, Emma C. E. Wassenaar, Floortje Mols, Dirk Jan A. R. Moes, +7 more
2citations -
191P Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study2024 Annals of Oncology article Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, M-L. Berres, I-P. Radu, Christoph Roderburg, +11 more
1citations -
1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
Rieke Nila Fischer, Julie George, Andreas Hans Scheel, Hans Anton Schloesser, Peter Brossart, W. Engel-Riedel, +14 more
1citations -
450MO Characterization of tumor-infiltrating lymphocytes and tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Markus Kleinberger, Christina Paiato, Erwin Tomasich, Maximilian Johannes Mair, Ariane Steindl, Zunamys Itzell Carrero, +7 more
1citations -
321P Results of an open-label, single-arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC)2025 Annals of Oncology article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
Christoph Roderburg, M.A. Gonzalez Carmona, ML Berres, Dominik Paul Modest, Raphael U. Mohr, Alexander Wree, +5 more
1citations -
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
Ulrike Anneliese Nitz, Oleg Gluz, Mathias Christgen, E.‐M. Grischke, Doris Augustin, Sherko Küemmel, +14 more
1citations -
438P Adjuvant nivolumab after neoadjuvant chemoradiotherapy and surgery for patients with esophageal or gastroesophageal junction cancer: A nationwide real-world matched comparison of overall survival
Rob H.A. Verhoeven, Steven C. Kuijper, Marije Slingerland, Bas P. L. Wijnhoven, Mark I. van Berge Henegouwen, Peter S.N. van Rossum, +4 more
1citations -
1683TiP OMIT trial: omitting therapeutic lymph node dissection in patients with stage IIIB/C melanoma and major pathological response in the index lymph node after neoadjuvant immunotherapy
Antonius W Schurink, Evalyn E.A.P. Mulder, Lukas B. Been, James van Bastelaar, Han J. Bonenkamp, Anneriet E. Dassen, +10 more
1citations -
1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence2024 Annals of Oncology article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, A. Huisman, Hans J.L. Timmer, L. Fagereng, Åslaug Helland, Bettina Ryll, +9 more
1citations -
O-4 Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium
Corinna Slawinski, Lee Malcomson, Jorge Barriuso, Hongwei Guo, Andrea Harkin, Timothy J. Iveson, +3 more
1citations -
649TiP PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer2021 Annals of Oncology article Medicine Prostate Cancer Diagnosis and Treatment Open access cited by 1 patent
Boris Alexander Hadaschik, Stefano Fanti, Piet Ost, Nina Tunariu, Cosimo DE NUNZIO, Luca Antoni, +3 more
1citations